$1.60
11.11% yesterday
Nasdaq, Apr 04, 09:19 pm CET
ISIN
US92023M1018
Symbol
GRI
Sector
Industry

Vallon Pharmaceuticals Inc Stock price

$1.51
-5.52 78.52% 1M
-4.58 75.19% 6M
-12.57 89.28% YTD
-116.28 98.72% 1Y
-81,680.09 100.00% 3Y
-349,001.69 100.00% 5Y
-349,001.69 100.00% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
+0.07 4.86%
ISIN
US92023M1018
Symbol
GRI
Sector
Industry

Key metrics

Market capitalization $790.00k
Enterprise Value $-4.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.48
P/B ratio (TTM) P/B ratio 0.20
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.24m
Free Cash Flow (TTM) Free Cash Flow $-8.61m
Cash position $5.03m
EPS (TTM) EPS $-203.36
Short interest 5.22%
Show more

Is Vallon Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Vallon Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Vallon Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Vallon Pharmaceuticals Inc:

Buy
100%

Financial data from Vallon Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.46 4.46
54% 54%
-
- Research and Development Expense 3.77 3.77
26% 26%
-
-8.23 -8.23
35% 35%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -8.24 -8.24
35% 35%
-
Net Profit -8.21 -8.21
38% 38%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vallon Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vallon Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
3 days ago
LA JOLLA, CA, April 02, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 1,388,888 shares of its commo...
Neutral
GlobeNewsWire
4 days ago
LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of a public offering of an aggregate of 1,388,888 shares of its common stock (or common stoc...
Neutral
GlobeNewsWire
5 days ago
Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases
More Vallon Pharmaceuticals Inc News

Company Profile

Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO W. Hertz
Employees 4
Founded 2009
Website www.gribio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today